Chemotherapy and cancer drugs
The latest chemistry news and research on chemotherapy and cancer drugs, including antibodies and immuno-oncology, from the Royal Society of Chemistry's magazine, Chemistry World
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
FeatureMore than a mirror-image: left-handed nucleic acids
Now a biological reality, researchers are starting to figure out the many roles of left-handed nucleic acids such as Z-DNA – from immunity to controlling our genetics. Rachel Brazil reports
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
BusinessPfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
ResearchAlphaFold works with other AI tools to go from target to hit molecule in 30 days
End-to-end AI drug discovery process predicts potential inhibitors for a protein implicated in liver cancer
-
ResearchRadium chelator researchers working to improve targeted cancer therapies
Oak Ridge National Lab team investigate factors underpinnning Ra2+ complex stability and selectivity in attempt to expand the therapeutic utility of radium-223
-
ResearchYeast engineered to ferment sugars into chemotherapy drug precursors
Semisynthesis offers new route to anticancer drug vinblastine
-
ResearchLight-activated cancer treatment uses tumour-targeting enzymes to cut side effects
Enzymatic activation of a photosensitive prodrug in cancerous cells shows promise in mice
-
BusinessMorphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
ResearchClick chemistry uses endogenous acrolein to activate cancer prodrug
Strategy could reduce chemotherapy side effects by selecting for cancerous cells
-
BusinessAntibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
-
ResearchNanoparticle can starve aggressive breast cancer cells of vital copper
A new engineered particle depletes copper from mitochondria, killing breast cancer cells in mice
-
ResearchIntroducing chirality to give organic electronics a twist
Medicinal molecules and electronic materials aren’t often found in the same research group. Meet Matthew Fuchter, who’s excelling at both
-
-
ResearchTargeted nanoparticles swell-up to kill cancer cells
Nanoparticles covered with charged ligands can kill errant cancer cells but leave normal cells unharmed
-
FeatureThe search for cancer vaccines
Claire Jarvis looks at ongoing work to prevent the disease – and convince a sceptical community of their seriousness
-
BusinessCancer and rare diseases dominated 2019 drug approvals
More streamlined review processes and changing R&D priorities have contributed to sustained increase in new medicines
-
ResearchTrefoil knots steer cancer drug leads in fresh direction
Chemists look to links and knots in the search for new cancer therapies
-
ResearchDroplet screening set to accelerate immunotherapies into the clinic
Single-cell technique eliminates inefficiencies when identifying immune cells active against specific cancers
-
ResearchNew family of peptides from extremophile show antibiotic promise
Scientists isolate salinipeptins from a bacterium living in America’s Dead Sea